Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Netarsudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 19/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 6/20 | 1.00 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netarsudil SCHEMBL114266 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29351219 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL21679903 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29478436 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL16036278 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29673273 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29677622 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL113753 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL113752 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL114348 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335507-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4218759-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | claimed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | claimed |
| CN-111936139-A | Mono (acid) salts of 6-aminoisoquinoline and uses thereof | 爱瑞制药公司 | 2020-11-13 | — | — | CN | claimed |
| US-20200276179-A1 | Combination Therapy | ALCON INC. (CH) | 2020-09-03 | — | — | US | claimed |
| US-20190322625-A1 | MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOF | ALCON INC. (CH) | 2019-10-24 | — | — | US | claimed |
| US-20180333405-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2018-11-22 | — | — | US | claimed |
| US-9993470-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | claimed |
| US-9931336-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | claimed |
| US-20170281613-A1 | Combination Therapy | ALCON INC. (CH) | 2017-10-05 | — | — | US | claimed |
| US-20160243105-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2016-08-25 | — | — | US | claimed |
| EP-2976080-A1 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2016-01-27 | — | — | EP | claimed |
| WO-2014144781-A1 | COMBINATION THERAPY | AERIE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-20140275160-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | claimed |
| EP-4335507-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4218759-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11707460-B2 | Ophthalmic compositions | AERIE PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2014144781-A1 | COMBINATION THERAPY | AERIE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275160-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275161-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322625-A1 | MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOF | AADAT, SLC10A1, SLC10A2 | ROCK2 3307/4885ROCK1 3706/4885MYLK4 2031/4885 |
| US-20140275160-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
| US-20160243105-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
| US-20170281613-A1 | Combination Therapy | PTGIR, PTGS1, PTGIS | ROCK2 430/4885ROCK1 582/4885MYLK4 608/4885 |
| US-20140275161-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
| US-20180333405-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 612/4885 |
| US-20200276179-A1 | Combination Therapy | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.